Fundamental Analysis of Inozyme Pharma Inc - Growth / Value Index


INZY - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 1594.53 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -1853.92 -3665.37 -134943.10 %
Price to Book 1670.79 1778.66 115593 % 2505.49
Price to Sales 72348.07 0 0 %
Enterprise Value to EBITDA Multiple -3.90 -3710.27 -163639.12 %


INZY - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -78.99 -48.53 14.33 % -19.65
Return On Asset -57.07 -33.94 29.55 % -13.19
Net Profit Margin -3902.43 0 0 % 0
Operating Profit Margin -4130.62 0 0 % 0
EBITDA Margin -4015.03 0 0 % 0


Highlights
Market Cap298143 K
Enterprise Value309234 K
Price/Book TTM1670.79
Outstanding Share61855.50 K
Float/ Outstanding Share61.29%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score0.927
Sloan Ratio-0.0079
Peter Lynch Fair Value0


INZY - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Poor Score of 21.38
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 1976.00 K % 100.00 %
Gross Profit -1152.00 K 9.94 % 40.52 %
EBITDA -79337.00 K 0.943 % 14.11 %
Net Profit -77112.00 K 1.65 % 8.37 %
EPS -0.0026 99.93 % NA


INZY - Stability Highlights

Stability Analysis

   Cash ratio of 12.84
   Tsr Stability Index - Poor Score of 32.81
   Altman Z Score of 0.792 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -20.45
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.325 676.95 % 0.387
Cash Ratio 12.84 47.78 %
Quick Ratio 0 0 % 14.05
Shareholders Equity 69.94 -17.77 %
Debt to EBITDA -0.678 -830.65 %


Historical Valuation Ratios of Inozyme Pharma Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Inozyme Pharma Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Inozyme Pharma Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Inozyme Pharma Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)